Pre-clinical characterization of [11C]R05013853 as a novel radiotracer for imaging of the glycine transporter type 1 by positron emission tomography

NeuroImage

Volumn 75, Issue , 2013, Pages 291-300

  Borroni, Edilio ^a   Zhou, Yun ^b   Ostrowitzki, Susanne ^a   Alberati, Daniela ^a   Kumar, Anil ^b   Hainzl, Dominik ^a   Hartung, Thomas ^a   Hilton, John ^b   Dannals, Robert F ^b   Wong, Dean F ^b,c  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Autoradiography; Bitopertin; Glycine transporter type 1 (GlyT1); PET; RG1678; Schizophrenia

Indexed keywords

BITOPERTIN; CARBON [(5 METHANESULFONYL 2 2,2,2 TRIFLUORO 1 METHYLETHOXY)PHENYL] [5 (TETRAHYDROPYRAN 4 YL) 1,3 DIHYDROISOINDOL 2 YL]METHANONE C 11; CARBON RO 5013852 C 11; GLYCINE TRANSPORTER 1; TRACER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BRAIN REGION; CEREBELLUM; CHEMICAL STRUCTURE; CONTROLLED STUDY; DOSIMETRY; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; NEUROIMAGING; NONHUMAN; PONS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; THALAMUS;

ANIMALS; AUTORADIOGRAPHY; BRAIN; CARBON RADIOISOTOPES; GLYCINE PLASMA MEMBRANE TRANSPORT PROTEINS; MALE; PAPIO; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SULFONES; TISSUE DISTRIBUTION;

EID: 84876450048     PISSN: 10538119     EISSN: 10959572     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2011.11.090     Document Type: Article

References (40)

1. Akaike H. An information criteria (AIC). Math. Sci. 1976, 14:5-9.
2. Alberati, D., Borroni, E., Moreau, J.L., Hainzl, D., Pinard, E., Wettstein, J.G., 2011. Partial occupancy of the glycine transporter type 1 in rat by RG1678 leads to efficacy in models relevant to schizophrenia. Schizophr. Bull. 37, Supplement 1, 286 ed.
3. Alberati, D., Moreau, J.L., Lengyel, J., Hauser, N., Mory, R., Borroni, E., Pinard, E., Knoflach, F., Schlottenberg, G., Hainzl, D., Wettstein, J., in press. Glycine transporter type 1 (GlyT1) inhibitor RG1678: a pharmacologic characterization of an investigational agent for the treatment of schizophrenia. Neuropharmacology. doi:. http://doi:10.1016/j.neuropharm.2011.11.008.
4. 11C]FLB 457: re-evaluation of the validity of using a cerebellar reference region. J. Cereb. Blood Flow Metab. 2007, 27:378-392.
5. Black K.J., Snyder A.Z., Koller J.M., Gado M.H., Perlmutter J.S. Template images for nonhuman primate neuroimaging: 1. Baboon. Neuroimage 2001, 14:736-743.
6. Borroni, E., Wong, D.F., Wallace, T.L., Zhou, Y., Kumar, A., Pinard, E., Alberati, D., 2011. Partial occupancy of the glycine transporter type 1 in monkey by RG1678 leads to efficacy in a model of prefrontal cortical function. Schizophr. Bull. 37, Supplement 1, 296 ed.
7. Buchanan R.W. Persistent negative symptoms in schizophrenia: an overview. Schizophr. Bull. 2007, 33:1013-1022.
8. Carson R.E. Parameter estimation in positron emission tomography. Positron Emission Tomography and Autoradiography: Principles and Applications for the Brain and Heart 1986, 347-390. Raven Press, New York. M. Phelps, J. Mazziotta, H. Schelbert (Eds.).
9. Cubelos B., Gimenez C., Zafra F. Localization of the GLYT1 glycine transporter at glutamatergic synapses in the rat brain. Cereb. Cortex 2005, 15:448-459.
10. Foussias G., Remington G. Negative symptoms in schizophrenia: avolition and Occam's razor. Schizophr. Bull. 2010, 36:359-369.
11. Gillings N.M., Bender D., Falborg L., Marthi K., Munk O.L., Cumming P. Kinetics of the metabolism of four PET radioligands in living minipigs. Nucl. Med. Biol. 2001, 28:97-104.
12. 11]GSK931145, a PET ligand for the glycine transporter 1 (GlyT1). Synapse 2011, 65:1319-1332.
13. Hamill T.G., Eng W., Jennings A., Lewis R., Thomas S., Wood S., Street L., Wisnoski D., Wolkenberg S., Lindsley C., Sanabria-Bohorquez S.M., Patel S., Riffel K., Ryan C., Cook J., Sur C., Burns H.D., Hargreaves R. The synthesis and preclinical evaluation in rhesus monkey of [(1)F]MK-6577 and [(1)(1)C]CMPyPB glycine transporter 1 positron emission tomography radiotracers. Synapse 2011, 65:261-270.
14. Heresco-Levy U., Javitt D.C., Ermilov M., Mordel C., Horowitz A., Kelly D. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br. J. Psychiatry 1996, 169:610-617.
15. Hilton J., Yokoi F., Dannals R.F., Ravert H.T., Szabo Z., Wong D.F. Column-switching HPLC for the analysis of plasma in PET imaging studies. Nucl. Med. Biol. 2000, 27:627-630.
16. Huang S.C., Barrio J.R., Phelps M.E. Neuroreceptor assay with positron emission tomography: equilibrium versus dynamic approaches. J. Cereb. Blood Flow Metab. 1986, 6:515-521.
17. Innis R.B., Cunningham V.J., Delforge J., Fujita M., Gjedde A., Gunn R.N., Holden J., Houle S., Huang S.C., Ichise M., Iida H., Ito H., Kimura Y., Koeppe R.A., Knudsen G.M., Knuuti J., Lammertsma A.A., Laruelle M., Logan J., Maguire R.P., Mintun M.A., Morris E.D., Parsey R., Price J.C., Slifstein M., Sossi V., Suhara T., Votaw J.R., Wong D.F., Carson R.E. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J. Cereb. Blood Flow Metab. 2007, 27:1533-1539.
18. Javitt D.C. Glutamate and schizophrenia: phencyclidine, N-methyl-d-aspartate receptors, and dopamine-glutamate interactions. Int. Rev. Neurobiol. 2007, 78:69-108.
19. 11C]flumazenil kinetics for the estimation of ligand transport rate and receptor distribution using positron emission tomography. J. Cereb. Blood Flow Metab. 1991, 11:735-744.
20. Lane H.Y., Chang Y.C., Liu Y.C., Chiu C.C., Tsai G.E. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Arch. Gen. Psychiatry 2005, 62:1196-1204.
21. 11C-methyl]-(-)-cocaine PET studies in human subjects. J. Cereb. Blood Flow Metab. 1990, 10:740-747.
22. Milev P., Ho B.C., Arndt S., Andreasen N.C. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am. J. Psychiatry 2005, 162:495-506.
23. Narvaez J.M., Twamley E.W., McKibbin C.L., Heaton R.K., Patterson T.L. Subjective and objective quality of life in schizophrenia. Schizophr. Res. 2008, 98:201-208.
24. Olney J.W., Newcomer J.W., Farber N.B. NMDA receptor hypofunction model of schizophrenia. J. Psychiatr. Res. 1999, 33:523-533.
25. 11C]GSK931145 as a novel ligand for imaging the type 1 glycine transporter with positron emission tomography. Synapse 2010, 64:542-549.
26. Pinard E., Alanine A., Alberati D., Bender M., Borroni E., Bourdeaux P., Brom V., Burner S., Fischer H., Hainzl D., Halm R., Hauser N., Jolidon S., Lengyel J., Norcross R.D., Puellmann B., Schmid P., Schmitt S., Stalder H., Wermuth R., Wettstein J., Zimmerli D. Selective GlyT inhibitors: discovery of [4-(3-Fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl]-[5-methansulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia. J. Med. Chem. 2010, 53:4603-4614.
27. Pinard E., Alberati D., Bender M., Borroni E., Brom V., Burner S., Fischer H., Hainzl D., Halm R., Hauser N., Jolidon S., Lengyel J., Marty H.P., Meyer T., Moreau J.L., Mory R., Narquizian R., Norcross R.D., Schmid P., Wermuth R., Zimmerli D. Discovery of benzoylisoindolines as a novel class of potent, selective and orally active GlyT1 inhibitors. Bioorg. Med. Chem. Lett. 2010, 20:6960-6965.
28. Pinard E., Burner S., Cueni P., Hartung T., Norcross R.D., Schmid P., Waldmeier P., Zielinski G., Ravert H.T., Holt D.P., Dannals R.F. Radiosynthesis of [5-[11C]methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methyl-ethoxy)-phenyl]-[5-(tetrahydro-pyran-4-yl)-1,3-dihydro-isoindol-2-yl]-methanone ([11C]RO5013853), a novel PET tracer for the glycine transporter type I (GlyT1). J. Labelled Comp. Radiopharm. 2011, 54:702-707.
29. Tek C., Kirkpatrick B., Buchanan R.W. A five-year follow up study of deficit and nondeficit schizophrenia. Schizophr. Res. 2001, 49:253-260.
30. Toyohara J., Ishiwata K., Sakata M., Wu J., Nishiyama S., Tsukada H., Hashimoto K. In vivo evaluation of of carbon-11-labelled non-sarcosine-based glycine transporter 1 inhibitors in mice and conscious monkeys. Nucl. Med. Biol. 2011, 38:517-527.
31. Tsai G., Yang P., Chung L.C., Lange N., Coyle J.T. D-serine added to antipsychotics for the treatment of schizophrenia. Biol. Psychiatry 1998, 44:1081-1089.
32. Tsai G., Lane H.Y., Yang P., Chong M.Y., Lange N. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol. Psychiatry 2004, 55:452-456.
33. Umbricht D., Yoo K., Youssef E., Dorflinger E., Martin-Facklam M., Bausch A., Arrowsmith R., Alberati D., Marder S., Santarelli L. Glycine transporter type 1 (GLYT1) inhibitor RG1678: positive results of the proof-of-concept study for the treatment of negative symptoms in schizophrenia. Neuropsychopharmacology 2010, 35:S320-S321.
34. Umbricht, D., Martin-Facklam, M., Pizzagalli, E., Youssef, K., Yoo, K., Dorflinger, E., Bausch, A., Arrowsmith, R., Alberati, D., Santarelli, L., 2011. Glycine transporter type 1 (GlyT1) inhibitor RG1678: results of the proof-of-concept study for the treatment of negative symptoms in schizophrenia. Schizophr Bull. 37, Suppl 1, 324 ed.
35. 11]RO5013853, a novel PET tracer for the Glycine Transporter Type 1 (GlyT1) in humans. NeuroImage 2013, 75:282-290.
36. Zhou Y., Endres C.J., Brasic J.R., Huang S.C., Wong D.F. Linear regression with spatial constraint to generate parametric images of ligand-receptor dynamic PET studies with a simplified reference tissue model. Neuroimage 2003, 18:975-989.
37. Zhou, Y., Brasic, J.R., Ye, W., Dogan, A., Hilton, J., Singer, H.S., Wong, D.F., 2004. Quantification of Cerebral Serotonin Binding in Normal Controls and Subjects with Tourette's syndrom Using [11C]MDL 100,907 and (+)[11C]McN 5652 Dynamic PET with Parametric Imaging Approach. NeuroImage 22(Suppl 2)T98 ed.
38. 11C]Pittsburgh compound B PET for early diagnosis of Alzheimer's disease. Neuroimage 2007, 36:298-312.
39. Borroni, E., Honer, M., Pinard, E., Hainzl, D., Alberati, D., submitted for publication. Pharmacological characterization of two novel radiotracers specific to the glycine transporter type 1: RO5013852 and RO5013853.
40. Martin-Facklam, M., Pizzagalli, F., Zhou, Y., Ostrowitzki, S., Raymont, V., Brašic, J.R, Parkar, N., Umbricht, D., Dannals, R.F. Goldwater, R., Wong, D.F., submitted for publication. Glycine Transporter Type 1 (GlyT1) occupancy by RG1678: a positron emission tomography study in healthy volunteers.